Member Info for Laura2022

Getech's corporate strategy is a response to these strong underlying trends and focuses on monetising the Company's capabilities across the geo-energy sector as well as seeking opportunities for transformational growth in critical minerals and potentially geological hydrogen. We are working on resolving our near-term liquidity concerns while at the same time evolving our offerings and unique propositions; growing our order book; expanding our pipeline; innovating our business models; and despite some near-term uncertainty over the route through to working capital self-sufficiency, we see exciting strategic prospects for the business.

Michael Covington

Chairman

Be good to see how the AGM goes and wherever KC turns up

May be of interest as to the wider precision therapy market

https://www.londonstockexchange.com/news-article/SYNC/syncona-adds-two-oncology-companies-to-portfolio/16528263

He was so rude at the Q and A re : val201

Good riddance to bad people

Over the last 3mths I have emailed 5 different companies

Peter has responded x 2 to earlier emails but not to the last one

1 BOD responds everything within 48hrs

2 3 others have never responded

Sienna

The A.I predicted tool is now going to be used with DoseMeRx, this post below is courtesy of KingH

DoseseMx is integrated into some of the biggest systems and platforms on earth !!!

DoseMe already integrated to

ILUN HEALTH- MERCK £207 Billion MC

Wolters Kluwer £24 Billion MC

Cerner £26.71 Billion MC

This study Sienna was based in Germany and almost certainly won't be PYC however shows the capability of predictive tools

Correctly predicted

The researchers, led by scientists at University College London and University Medical Center Goettingen, in Germany, took blood samples from a group of people with Parkinson's and another without, to identify eight major proteins most likely to predict who would develop the condition.

They then tested blood from 72 patients at risk of brain disorders such as Parkinson's for those eight protein markers - and followed them up over 10 years.

Using the AI tool, they correctly predicted 16 would develop Parkinson’s - up to seven years before symptoms began.

In total, the test predicted 79% would develop the disease - and the researchers are still following up other patients to confirm its accuracy.

Hi sienna

Not sure , as PYC mainly/primarily oncology BUT does show A.I for drug discovery is big news last 12mths

I have taken my profits from 0.8p

Well done everyone

Excellent news, we all felt 3mths ago that Dr C was making a strategic move

Across the whole market it is very tough despite the FTSE being at record highs ,most AIM companies I notice have discussion boards which are toxic and where the company have released very little positive news for 9mths +

Yet PYC have

1 produced a record H1 and cut losses

2 delivered nearly £1mln in signed orders since June

3 re engaged with DoseMeRx

4 gone from an undisclosed pipliene to £1mln to £1.5mln and...one assumes.. still growing

5 Continued to diversify clients

6 last 3 contracts the incrementally largest in their history

7 new CEO

as for share4,theyvhave spent 2yrs trolling here and own no shares on any stock seemingly

Sad

The UK’s main stock market retook its crown as Europe’s most valuable for the first time in nearly two years, data shows.

The total value of companies listed on the London Stock Exchange (LSE) hit $3.18tn on Monday, overtaking the $3.13tn total value of companies listed in Paris, according to Bloomberg data.

Both valuations have shifted since and remain close, but analysts describe it as a milestone.

They say the French market has slumped because of the uncertainty around its election, while the UK market is recovering after several years of underperformance.

The LSE had been Europe’s largest stock market for many years before November 2022 when it was overtaken.

PYC she partners and Inaphaea were at the recent biontech conference that PYC attended

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update from its wholly owned subsidiary Inaphaea BioLabs Limited ("Inaphaea").

Inaphaea is pleased to confirm the execution of a revenue-bearing contract for the provision of Patient Derived Cell ("PDC") based services with a new client; a US-based biotech company.  The contract is a multi-stage project and encompasses analysis and provision of RNA data, acquired as part of the scientific package from Imagen Therapeutics, in

PYC should be vast multiples of where we are now

https://www.fiercehealthcare.com/health-tech/tempus-ai-shares-jump-15-stock-market-debut-ipo-priced-over-6b-valuation

Tempus AI shares jump 15% in stock market debut as IPO priced at over $6B valuation

By Heather LandiJun 14, 2024 1:00pm

Tempus initial public offering Precision Medicine Artificial Intelligence

Share 

In its Securities and Exchange Commission filing, Tempus AI said it aims to "unlock the power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare." (monsitj/GettyImages)

Tempus AI, a precision medicine company that, as its name implies, uses artificial intelligence to process medical data, popped in its stock market debut Friday, with shares jumping 15%.

Very best of luck

The AIM market needs more people like you to hold these BODS to account who have had it to easy since Covid , there are also action groups on several others like VAL

Well done and best of luck

Options under consideration include creation of a dedicated business unit, creation of a wholly owned subsidiary or a joint venture with a party with complementary technology/ capabilities.  As further progress is made towards one of these, further updates will be provided accordingly

2nd half of 2024 should be good, with this JV and also bio statistics division. Interesting is that PYC are contemplating a spin off business (NASDAQ?)

nitially on a research basis, to selected US clients.  It is expected that the software will be made available in the second half of 2024.  T

Https://www.investegate.co.uk/announcement/rns/physiomics--pyc/doseme-precision-dosing-modeling-functionality/8259973

They've outlined how this software has come about due to £350k of grant funding. Add in the man hours + data studies this is indeed looking like a potential standalone business with big potential which needs capital and probably a separate listing to fulfil its potential. Interesting also the owners of DoseMeRX are Private Equity so could actually play a part in funding such an initiative.